Erratum to A genetic case-control study confirms the implication of smad7 and tnf locus in the development of proliferative vitreoretinopathy (Invest Ophthalmol Vis Sci (2013), 54, (1665-1678), 10.1167/iovs.12-10931);A genetic case-control study confirms the implication of SMAD7 and TNF locus in the development of proliferative vitreoretinopathy

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 3, 2013, Pages 1665-1678

  Rojas, Jimena ^a   Fernandez, Itziar ^b   Pastor, Jose C ^a,b,c   MacLaren, Robert E ^d   Ramkissoon, Yashim ^d   Harsum, Steven ^d   Charteris, David G ^d   Van Meurs, Jan C ^e   Amarakoon, Sankha ^e   Ruiz Moreno, Jose M ^f,j   Rocha Sousa, Amandio ^g   Brion, Maria ^h,i   Carracedo, Angel ^h,i  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^d MOORFIELDS EYE HOSPITAL   (United Kingdom)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f VISSUM Corporacion Oftalmologica   (Spain)

^g UNIVERSITY OF PORTO   (Portugal)

^h HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

ⁱ UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^j UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; MATRILYSIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC SUBUNIT GAMMA; PHOSPHATIDYLINOSITOL KINASE; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SCATTER FACTOR; SMAD3 PROTEIN; SMAD7 PROTEIN; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLELE; ARTICLE; CASE CONTROL STUDY; CILIARY DISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VITRECTOMY; VITREORETINOPATHY;

EID: 84875457635     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10931a     Document Type: Erratum

References (49)

1. Pastor JC, Fernández I, Rodríguez de la Rúa E, et al. Surgical outcomes for primary rhegmatogenous retinal detachments in phakic and pseudophakic patients: the Retina 1 Project-report 2. Br J Ophthalmol. 2008;92:378-382.
2. Wiedemann P. Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy and retinal degeneration. Surv Ophthalmol. 1992;36:373-384.
3. Delyfer MN, Raffelsberger W, Mercier D, et al. Transcriptomic analysis of human retinal detachment reveals both inflammatory response and photoreceptor death. PLoS One. 2011;6: e28791.
4. El-Ghrably IA, Dua HS, Orr GM, Fischer D, Tighe PJ. Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. Br J Ophthalmol. 2001;85: 461-470.
5. Banerjee S, Savant V, Scott RA, et al. Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders. Invest Ophthalmol Vis Sci. 2007;48:2203-2207.
6. Campochiaro PA, Hackett SF, Vinores SA. Growth factors in the retina and retinal pigmented epithelium. Prog Ret Eye Res. 1996;15:547-567.
7. Charteris DG. Growth factors in proliferative vitreoretinopathy. Br J Ophthalmol. 1998;82:106.
8. Liou GI, Pakalnis VA, Matragoon S, et al. HGF regulation of RPE proliferation in an IL-1beta/retinal hole-induced rabbit model of PVR. Mol Vis. 2002;8:494-501.
9. Hinton DR, He S, Jin ML, et al. Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye. 2002;16:422-428.
10. Choudhury P, Chen W, Hunt RC. Production of platelet-derived growth factor by interleukin-1 beta and transforming growth factorbeta-stimulated retinal pigment epithelial cells leads to contraction of collagen gels. Invest Ophthalmol Vis Sci. 1997; 38:824-833.
11. Harada C, Mitamura Y, Harada T. The role of cytokines and trophic factors in epiretinal membranes: involvement of signal transduction in glial cells. Prog Retin Eye Res. 2006;25:149-164.
12. Mukherjee S, Guidry C. The insulin-like growth factor system modulates retinal pigment epithelial cell tractional force generation. Invest Ophthalmol Vis Sci. 2007;48:1892-1899.
13. Pastor JC. Rodriguez de la Rua E, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002;21:127-144.
14. Rodriguez de la Rua E, Pastor JC, Aragón J, et al. Interaction between surgical procedure for repairing retinal detachment and clinical risk factors for proliferative vitreoretinopathy. Curr Eye Res. 2005;30:147-153.
15. Asaria RH, Kon CH, Bunce C, et al. How to predict proliferative vitreoretinopathy: a prospective study. Ophthalmology. 2001;108:1184-1186.
16. Charteris DG, Aylward GW, Wong D, et al. A randomized controlled trial of combined 5-fluorouracil and low-molecularweight heparin in management of established proliferative vitreoretinopathy. Ophthalmology. 2004;111:2240-2245.
17. Turgut B, Uyar F, Ustundag B, et al. The impact of Tracolimus on growth factors experimental proliferative vitreoretinopathy. Retina. 2012;32:232-241.
18. Nassar K, Lüke J, Lüke M, et al. The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR). Graefes Arch Clin Exp Ophthalmol. 2011;249: 1649-1660.
19. Ordovas JM, Mooser V. Nutrigenomics and nutrigenetics. Curr Opin Lipidol. 2004;15:101-108.
20. Brennan P. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis. 2002;23:381-387.
21. Sanabria Ruiz-Colmenares MR, Pastor Jimeno JC, Garrote Adrados JA, Telleria Orriols JJ, Yugueros Fernández MI. Cytokine gene polymorphisms in retinal detachment patients with and without proliferative vitreoretinopathy: a preliminary study. Acta Ophthalmol Scand. 2006;84:309-313.
22. Rojas J, Fernandez I, Pastor JC, et al. Development of predictive models of proliferative vitreoretinopathy based on genetic variables: the Retina 4 project. Invest Ophthalmol Vis Sci. 2009;50:2384-2390.
23. Crawford DC, Nickerson DA. Definition and clinical importance of haplotypes. Annu Rev Med. 2005;56:303-320.
24. Dempfle A, Scherag A, Hein R, et al. Gene-environment interactions for complex traits: definitions, methodological requirements and challenges. Eur J Hum Gen. 2008;16:1164-1172.
25. Machemer R, Aaberg TM, Freeman HM, et al. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991;112:159-165.
26. Buetow KH, Edmonson M, MacDonald R, et al. Highthroughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci U S A. 2001;98:581-584.
27. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998;43:3-18.
28. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005; 21:263-265.
29. Cuchacovich M, Soto L, Edwardes M, et al. Tumour necrosis factor (TNF)alpha-308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid artritis. Scand J Rheumatol. 2006;35:435-440.
30. Glossop JR, Dawes PT, Nixon NB, Mattey DL. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis. Arthritis Res Ther. 2005;7:R1227-R1234.
31. Karban AS, Okazaki T, Panhuysen CI, et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet. 2004;13: 35-45.
32. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem. 2001;276:7549-7558.
33. Drumm ML, Konstan MW, Schluchter MD, et al. Gene Modifier Study Group. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med. 2005;353:1443-1453.
34. Fallin D, Schork NJ. Accuracy of haplotype frequency estimation for biallelic loci via the expectation-maximization algorithm for uphased diploid genotype data. Am J Hum Genet. 2000;67:947-959.
35. Rosenberg PS, Che A, Chen BE. Multiple hypothesis testing strategies for genetic case-controlled association studies. Stat Med. 2006;25:3134-3149.
36. Simes RJ. An improved Bonferroni procedure for multiple tests of significance. Biometrika. 1986;73:751-754.
37. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B Methodol. 1995;57:289-300.
38. R Development Core Team 2007. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Available at: http://www.R-project.org. Accessed July 10, 2012.
39. González JR, Armengol L, Solé X, et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics. 2007;23:644-645.
40. Sinnwell Jason P, Schaid Daniel J. 2005;haplo. stats: Statistical Analysis of Haplotypes with Traits and Covariates when Linkage Phase is Ambiguous. R package version 1.2.2. Available at: http://CRAN.R-project.org/package=haplo.stats. Accessed July 22, 2012.
41. Daly AK, Day CP. Candidate gene case-control association studies: advantages and potential pitfalls. Br J Clin Pharmacol. 2001;52:489-499.
42. de la Rúa ER, Pastor JC, Fernández I, et al. Non-complicated retinal detachment management: variations in 4 years. Retina 1 project; report 1. Br J Ophthalmol. 2008;92:523-525.
43. Ioannidis JP. Non-replication and inconsistency in the genomewide association setting. Hum Hered. 2007;64:203-213.
44. Limb GA, Hollifield RD, Webster L, et al. Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophthalmol Vis Sci. 2001;42:1586-1591.
45. El-Ghrably IA, Dua HS, Orr GM, Fischer D, Tighe PJ. Detection of cytokine mRNA production in infiltrating cells in proliferative vitreoretinopathy using reverse transcription polymerase chain reaction. Br J Ophthalmol. 1999;83:1296-1299.
46. El Ghrably I, Powe DG, Orr G, et al. Apoptosis in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2004;45:1473-1479.
47. Saika S, Yamanaka O, Flanders KC, et al. Epithelial-mesenchymal transition as a therapeutic target for prevention of ocular tissue fibrosis. Endocr Metab Immune Disord Drug Targets. 2008;8:69-76.
48. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol. 2004;85:47-64.
49. Saika S, Yamanaka O, Nishikawa-Ishida I, et al. Effect of Smad7 gene overexpression on transforming growth factor betainduced retinal pigment fibrosis in a proliferative vitreoretinopathy mouse model. Arch Ophthalmol. 2007;125:647-654.